REGNRegeneron Pharmaceuticals, Inc.

REGN Stock Price, Valuation & Chart | Regeneron Pharmaceuticals, Inc.

Compare

$778.36+25.24 (+3.35%)

At close · 14 Oct 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology

Overview Financials Dividends Ratios

REGN Historical price chart

REGN Key Stats

Market Capitalization80.19B

PE Ratio17.06

EPS45.63

Trading Volume878.01K

Today's High/Low781.84/755.21

Dividend Yield0.48

52 Week High/Low859.34/564.0

Shares Outstanding103.02M

REGN Financial Statement

REGN Analyst ratings

REGN Analysis & performance metrics

REGN Company profile

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products…

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion,…

REGN Management team

Name

Position

Leonard S. Schleifer M.D., Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Co-Chairman

Bob McCowanCTO

Senior Vice President of IT & Chief Information Officer

Melissa Lozner

Senior Vice President & Chief Compliance Officer

Patrice Gilooly

Senior Vice President of Quality Assurance & Operations

Ryan Crowe

Senior Vice President of Investor Relations & Strategic Analysis

Christopher R. Fenimore CPACFO

Executive Vice President of Finance & Chief Financial Officer

Daniel P. Van Plew

Executive Vice President and GM of Industrial Operations & Product Supply

George D. Yancopoulos M.D., Ph.D.

Co-Founder, President, Chief Scientific Officer & Co-Chairman

Name

Position

Leonard S. Schleifer M.D., Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Co-Chairman

Bob McCowanCTO

Senior Vice President of IT & Chief Information Officer

Melissa Lozner

Senior Vice President & Chief Compliance Officer

Patrice Gilooly

Senior Vice President of Quality Assurance & Operations

Ryan Crowe

Senior Vice President of Investor Relations & Strategic Analysis

Christopher R. Fenimore CPACFO

Executive Vice President of Finance & Chief Financial Officer

Daniel P. Van Plew

Executive Vice President and GM of Industrial Operations & Product Supply

George D. Yancopoulos M.D., Ph.D.

Co-Founder, President, Chief Scientific Officer & Co-Chairman

Management Team

Leonard S. Schleifer M.D., Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Co-Chairman

Bob McCowanCTO

Senior Vice President of IT & Chief Information Officer

Melissa Lozner

Senior Vice President & Chief Compliance Officer

Patrice Gilooly

Senior Vice President of Quality Assurance & Operations

Ryan Crowe

Senior Vice President of Investor Relations & Strategic Analysis

Christopher R. Fenimore CPACFO

Executive Vice President of Finance & Chief Financial Officer

Daniel P. Van Plew

Executive Vice President and GM of Industrial Operations & Product Supply

George D. Yancopoulos M.D., Ph.D.

Co-Founder, President, Chief Scientific Officer & Co-Chairman

Management

Leonard S. Schleifer M.D., Ph.D.CEO

Co-Founder, President, Chief Executive Officer & Co-Chairman

Bob McCowanCTO

Senior Vice President of IT & Chief Information Officer

Melissa Lozner

Senior Vice President & Chief Compliance Officer

Patrice Gilooly

Senior Vice President of Quality Assurance & Operations

Ryan Crowe

Senior Vice President of Investor Relations & Strategic Analysis

Christopher R. Fenimore CPACFO

Executive Vice President of Finance & Chief Financial Officer

Daniel P. Van Plew

Executive Vice President and GM of Industrial Operations & Product Supply

George D. Yancopoulos M.D., Ph.D.

Co-Founder, President, Chief Scientific Officer & Co-Chairman

Total 8 executives

REGN Frequently asked questions

What is Regeneron Pharmaceuticals, Inc. (REGN) Stock Price?

Current stock price of Regeneron Pharmaceuticals, Inc. (REGN) stock is $778.36. The stock price is +3.35% higher in the session. The intraday range can be seen from this page. Volume of Regeneron Pharmaceuticals, Inc. (REGN) stock is 878.01K.

Last updated at 14 Oct 2026, 08:00 pm.

Why is the Regeneron Pharmaceuticals, Inc. (REGN) stock price going up or down today?

The stock price of Regeneron Pharmaceuticals, Inc. (REGN) can change with earnings, company news, and overall market sentiment. Regeneron Pharmaceuticals, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Regeneron Pharmaceuticals, Inc. stock expensive at its current price?

Whether Regeneron Pharmaceuticals, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for REGN on this page is 17.06. EPS on this page is 45.63. Compare those figures with peers and growth expectations before deciding if the current Regeneron Pharmaceuticals, Inc. price is justified.

How has the stock price of Regeneron Pharmaceuticals, Inc. (REGN) performed historically?

Historical performance for Regeneron Pharmaceuticals, Inc. (REGN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how REGN reacted to past earnings and market events.

Should I buy Regeneron Pharmaceuticals, Inc. (REGN) stock, at this price?

Buying Regeneron Pharmaceuticals, Inc. (REGN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.